Cardiovascular Systems Stock Forecast, Price & News

Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

Is Cardiovascular Systems a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems or view top-rated stocks.

How has Cardiovascular Systems' stock price been impacted by COVID-19 (Coronavirus)?

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CSII shares have decreased by 50.2% and is now trading at $18.07.
View which stocks have been most impacted by COVID-19.

Are investors shorting Cardiovascular Systems?

Cardiovascular Systems saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,500,000 shares, an increase of 72.2% from the December 15th total of 870,900 shares. Based on an average trading volume of 384,100 shares, the days-to-cover ratio is currently 3.9 days. Approximately 3.8% of the shares of the company are short sold.
View Cardiovascular Systems' Short Interest.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Cardiovascular Systems.

How can I listen to Cardiovascular Systems' earnings call?

Cardiovascular Systems will be holding an earnings conference call on Thursday, February 3rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) issued its quarterly earnings results on Monday, November, 8th. The medical device company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.12. The medical device company earned $58.40 million during the quarter, compared to analyst estimates of $63.72 million. Cardiovascular Systems had a negative net margin of 7.77% and a negative trailing twelve-month return on equity of 7.40%. The firm's revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.05) EPS.
View Cardiovascular Systems' earnings history.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems issued an update on its FY 2022 earnings guidance on Tuesday, December, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $265 million-$285 million, compared to the consensus revenue estimate of $295.53 million.

What price target have analysts set for CSII?

7 analysts have issued 12-month price targets for Cardiovascular Systems' shares. Their forecasts range from $40.00 to $49.00. On average, they expect Cardiovascular Systems' share price to reach $43.40 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view top-rated stocks among Wall Street analysts.

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the following people:

• Scott R. Ward, Chairman, President & Chief Executive Officer
• Rhonda J. Robb, Chief Operating Officer
• Jeffrey S. Points, Chief Financial Officer
• Ryan D. Egeland, Chief Medical Officer
• Sandra M. Sedo, Chief Compliance Officer

What is Scott Ward's approval rating as Cardiovascular Systems' CEO?

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Who are some of Cardiovascular Systems' key competitors?

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of CSII's competitors.

What other stocks do shareholders of Cardiovascular Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Procter & Gamble (PG).

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.44%), M&G Investment Management Ltd. (0.17%), Russell Investments Group Ltd. (0.10%), State of Alaska Department of Revenue (0.07%) and Diversified Trust Co (0.04%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, Sandra Sedo and Scott R Ward.
View institutional ownership trends for Cardiovascular Systems.

Which major investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Diversified Trust Co, and State of Alaska Department of Revenue.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

Which major investors are buying Cardiovascular Systems stock?

CSII stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and M&G Investment Management Ltd.. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, and Scott R Ward.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $18.07.

How much money does Cardiovascular Systems make?

Cardiovascular Systems has a market capitalization of $732.76 million and generates $258.97 million in revenue each year. The medical device company earns $-13.42 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Cardiovascular Systems have?

Cardiovascular Systems employs 779 workers across the globe.

When was Cardiovascular Systems founded?

Cardiovascular Systems was founded in 1989.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is www.csi360.com.

Where are Cardiovascular Systems' headquarters?

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at (651) 259-1600, via email at [email protected], or via fax at 612-677-3355.